Long-Term Outcomes of Adult Patients with Homocystinuria before and after Newborn Screening

Abstract

by Kenji Yamada,Kazunori Yokoyama,Kikumaro Aoki,Takeshi Taketani andSeiji Yamaguchi
Int. J. Neonatal Screen. 2020, 6(3), 60; https://doi.org/10.3390/ijns6030060 - 15 FEB 2022
Cited by 11 | Viewed by 3231
Abstract
Background: Homocystinuria (HCU) is a rare inherited metabolic disease. In Japan, newborn screening (NBS) for HCU (cystathionine β-synthase deficiency) was initiated in 1977. We compared the outcomes between patients detected by NBS (NBS group) and clinically detected patients (non-NBS group). Methods: We administered questionnaires about clinical symptoms and social conditions to 16 attending physicians of 19 adult HCU patients treated with methionine-free formula. Results: Eighteen patients (nine patients each in the NBS and non-NBS groups) participated. The frequency of patients with ocular, vascular, central nervous system, and skeletal symptoms in the NBS group was lower than that in the non-NBS group. Intellectual disability was observed in one and eight patients in the NBS and non-NBS groups, respectively. Concerning their social conditions, all patients in the NBS group were employed or still attending school, while only two patients in the non-NBS group were employed. Three of the four patients who discontinued treatment presented some symptoms, even in the NBS group. Conclusion: The social and intellectual outcomes of adult Japanese patients with HCU detected by NBS were favorable. However, even in the patients in the NBS group, some symptoms might not be preventable without continuous treatment. Full article
(This article belongs to the Collection Newborn Screening in Japan)
4 pages, 528 KiB